Danaher Corporation $DHR Stock Purchased by Hummer Financial Advisory Services Inc

Hummer Financial Advisory Services Inc boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 278.3% in the third quarter, HoldingsChannel reports. The firm owned 6,185 shares of the conglomerate’s stock after buying an additional 4,550 shares during the period. Danaher accounts for about 1.1% of Hummer Financial Advisory Services Inc’s holdings, making the stock its 22nd biggest holding. Hummer Financial Advisory Services Inc’s holdings in Danaher were worth $1,370,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in DHR. BlackRock Inc. purchased a new position in shares of Danaher during the 2nd quarter valued at about $10,492,520,000. Jupiter Topco LLC acquired a new position in shares of Danaher in the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP purchased a new stake in shares of Danaher in the second quarter worth about $1,287,949,000. Bank of America Corp DE purchased a new stake in shares of Danaher in the second quarter worth about $993,846,000. Finally, Legal & General Group Plc acquired a new stake in Danaher during the second quarter worth about $801,056,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR stock opened at $217.33 on Friday. The company has a market capitalization of $152.78 billion, a P/E ratio of 38.60, a P/E/G ratio of 2.72 and a beta of 0.76. The business’s 50 day moving average is $210.88 and its two-hundred day moving average is $194.44. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business’s revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.77 earnings per share. Analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Analyst Ratings Changes

Several brokerages recently weighed in on DHR. Evercore reiterated an “outperform” rating and set a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Royal Bank Of Canada lifted their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday. Guggenheim boosted their target price on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Stifel Nicolaus lowered their price target on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Finally, UBS Group started coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.23.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.